arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Medpace Holdings, Inc.

MEDP Health Care Biotechnology: Commercial Physical & Biological Resarch
$591.29
Today
as of Sep 4, 16:51 ET
Last 30 days +3.56% Jul 28 → Sep 04
$566.99 $581.42 $595.86 $610.30 $624.73 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$585.10
High
$596.00
Low
$585.00
Volume
$145,044
Avg Vol
$324,402
Mkt Cap
$16.1B
P/E (TTM)
48.48
Beta
—
52w High
$677.90
52w Low
$373.00
Div Yield
—
Shares Out
$28M

Recent Press Releases & News last 60 days · 25 items

Aug 31 · 20:19 MT Newswires
Medpace Holdings Insider Sold Shares Worth $403,176, According to a Recent SEC Filing
Aug 28 · 20:37 MT Newswires
Medpace Holdings Insider Sold Shares Worth $2,383,511, According to a Recent SEC Filing
Aug 27 · 20:33 StockStory
Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$373
$678
72% of range
Avg surprise (last 2)
+11.6%
Avg reaction (last 2)
-1.7%
0% positive
Latest IV / EM
39%
EM ±6.1% · $590 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$1.93$2.52$3.11$3.69$4.28 Actual $2.27Actual $1.93Actual $2.22Actual $3.20Actual $2.75Actual $3.01Actual $3.67Est $3.06Actual $3.10Est $3.00Actual $3.86Actual $4.28Actual $4.25 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$0$186M$371M$557M$743M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $4.25 — — — — financials
Tue Mar 31, 2026Mar 2026 $4.28 — — — — financials
Tue Sep 30, 2025Sep 2025 $3.86 — — — — financials
Mon Jul 21, 2025Jun/2025 $3.10 $3.00 +3.3% — -1.0% earnings
Mon Apr 21, 2025Mar/2025 $3.67 $3.06 +19.9% — -2.5% earnings
Mon Sep 30, 2024Sep 2024 $3.01 — — — — financials
Sun Jun 30, 2024Jun 2024 $2.75 — — — — financials
Sun Mar 31, 2024Mar 2024 $3.20 — — — — financials
Sat Sep 30, 2023Sep 2023 $2.22 — — — — financials
Fri Jun 30, 2023Jun 2023 $1.93 — — — — financials
Fri Mar 31, 2023Mar 2023 $2.27 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$707M$707M—$660M$603M$559M—$533M
Cost of revenue————————
Gross profit————————
Operating income$147M$142M—$142M$126M$114M—$112M
Net income$121M$124M—$111M$90M$115M—$96M
EPS (diluted)$4.25$4.28—$3.86$3.10$3.67—$3.01

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$503M$653M$497M$285M$46M$441M$669M$657M
Inventory————————
Total current assets$1.05B$1.14B$990M$737M$521M$821M$1.03B$1.03B
Total assets$2.06B$2.13B$1.98B$1.75B$1.57B$1.90B$2.10B$2.08B
Long-term debt————————
Total liabilities$1.62B$1.53B$1.52B$1.46B$1.40B$1.30B$1.28B$1.20B
Total equity$434M$598M$459M$294M$172M$594M$826M$881M

Implied volatility — last 90 days

25%39%52%65%79% Jun 07 — IV 51% · EM ±7.1%Jun 08 — IV 45% · EM ±5.9%Jun 09 — IV 47% · EM ±5.9%Jun 10 — IV 50% · EM ±5.9%Jun 11 — IV 45% · EM ±5.0%Jun 12 — IV 45% · EM ±4.6%Jun 15 — IV 55% · EM ±4.0%Jun 16 — IV 59% · EM ±3.5%Jun 17 — IV 59% · EM ±2.4%Jun 19 — IV 39% · EM ±8.5%Jun 22 — IV 38% · EM ±8.0%Jun 23 — IV 36% · EM ±7.3%Jun 24 — IV 41% · EM ±8.1%Jun 25 — IV 39% · EM ±7.7%Jun 26 — IV 38% · EM ±7.3%Jun 29 — IV 39% · EM ±6.9%Jun 30 — IV 38% · EM ±6.6%Jul 01 — IV 40% · EM ±6.7%Jul 02 — IV 38% · EM ±6.1%Jul 03 — IV 39% · EM ±6.1%Jul 06 — IV 42% · EM ±5.8%Jul 07 — IV 41% · EM ±5.4%Jul 08 — IV 43% · EM ±5.4%Jul 09 — IV 42% · EM ±5.0%Jul 10 — IV 37% · EM ±4.1%Jul 13 — IV 49% · EM ±4.1%Jul 14 — IV 54% · EM ±3.9%Jul 15 — IV 48% · EM ±2.8%Jul 16 — IV 56% · EM ±2.3%Jul 20 — IV 65% · EM ±15.4%Jul 21 — IV 67% · EM ±15.5%Jul 22 — IV 79% · EM ±18.1%Jul 23 — IV 39% · EM ±8.8%Jul 24 — IV 36% · EM ±8.0%Jul 27 — IV 37% · EM ±7.8%Jul 28 — IV 38% · EM ±7.9%Jul 29 — IV 56% · EM ±11.2%Jul 30 — IV 37% · EM ±7.2%Jul 31 — IV 37% · EM ±7.1%Aug 03 — IV 39% · EM ±6.9%Aug 04 — IV 37% · EM ±6.3%Aug 05 — IV 34% · EM ±5.6%Aug 06 — IV 36% · EM ±5.8%Aug 07 — IV 34% · EM ±5.4%Aug 10 — IV 29% · EM ±4.0%Aug 11 — IV 26% · EM ±3.4%Aug 12 — IV 28% · EM ±3.6%Aug 13 — IV 34% · EM ±4.0%Aug 14 — IV 30% · EM ±3.3%Aug 17 — IV 36% · EM ±3.0%Aug 18 — IV 35% · EM ±2.6%Aug 19 — IV 26% · EM ±1.6%Aug 20 — IV 59% · EM ±2.4%Aug 24 — IV 31% · EM ±6.5%Aug 25 — IV 32% · EM ±6.5%Aug 26 — IV 30% · EM ±6.1%Aug 27 — IV 29% · EM ±5.7%Aug 28 — IV 30% · EM ±5.8%Aug 31 — IV 33% · EM ±5.9%Sep 01 — IV 32% · EM ±5.5%Sep 02 — IV 34% · EM ±5.6%Sep 03 — IV 31% · EM ±5.1%Sep 04 — IV 39% · EM ±6.1%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in